semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed: Post-void residual: 71 mL Prostate volume (TRUS): 63 mL Prostate-specific antigen (PSA) level: 3.5 ng/mL His recent blood chemistry (3 days ago) was normal: Hgb: 13.6 g/dl WBC: 133000 /mm3 Plt: 370000 /ml PT: 12 second PTT: 34 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 40.0-75.0,  Stress Urinary Incontinence Urethral Intrinsic Sphincter Deficiency Men or women from 40 to 75 years old, suffering from urinary incontinence since at least 6 months and candidate for a surgical treatment (artificial urinary sphincter, synthetic compressive tapes or adjustable balloons). The myofiber implantation procedure will be proposed after failure of pelvic floor exercises The observation of urine leakage during cough in consultation or during urodynamic (with absence of abnormal vesical contraction) and a score MHU > 2 (domain of stress urinary incontinence) will be considered as the main diagnostic criteria An urethral closure pressure lower than 40 cm H20 will be the main urodynamic diagnostic criterion For women: a negative test, and Qtip test<40° (c.f. annex) demonstrating the absence of vesica-urethral hypermobility. 24 hours Pad test > 20g  Incapacity to answer the questionnaires of evaluation History of pelvic radiotherapy Disorder of hemostasis Untreated urinary infection Genetically determined or acquired muscular disease Neurological disorder (Parkinson's disease, multiple sclerosis, spina medullary traumatism) The patients suffering from stress urinary incontinence due to vesica-urethral hypermobility (positive test and Qtip test >40°) will not be included in the study because the referenced treatment is the implantation of a vaginal tape supporting the urethra Incomplete vesical emptying. Residual volume > 20% of the urinated volume with a micturition >150cc Dysuria: maximum urinary flow < 12 ml/sec, IPSS score>7 or score (men) or MHU dysuria domain none equal to 0 at woman Vesical instability (bladder contraction > 10 cm H20 during the vesical filling of the cysto-manometry). bladder capacity (B3) < 300 DC
Patient description: The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed: Post-void residual: 71 mL Prostate volume (TRUS): 63 mL Prostate-specific antigen (PSA) level: 3.5 ng/mL His recent blood chemistry (3 days ago) was normal: Hgb: 13.6 g/dl WBC: 133000 /mm3 Plt: 370000 /ml PT: 12 second PTT: 34 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Prostatic Neoplasms Prostate Cancer Histologically or cytologically confirmed adenocarcinoma (malignant epithelial tumor with a glandular organization)of the prostate (a gland in the male reproductive system found below the bladder and in front of the rectum), but not with neuroendocrine (specialized neurons that produce hormones, such as neuropeptides or biogenic amines) differentiation or of small cell histology Prior chemotherapy (treatment of disease, usually cancer, by chemical agents) for prostate cancer with regimen(s) containing docetaxel Documented prostate specific antigen (PSA) progression according to Prostate Specific Antigen Working Group (PSAWG) with a PSA more than (>) 5 nanogram per milliliter (ng/mL) or objective progression by Response Evaluation in Solid Tumors (RESIST) Ongoing androgen deprivation with serum testosterone less than (<) 50 nanogram per deciliter (ng/dL) Eastern Cooperative Oncology Group (ECOG) Performance Status of less than equal to (<=) 2 (Karnofsky Performance Status >= 50 percent)  Active or uncontrolled autoimmune disease (disorder in which a person's immune system attacks parts of his or her own body) that may require corticosteroid therapy Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection Uncontrolled hypertension (high blood pressure) Hemoglobin <=9.0 gram per deciliter (g/dL) without growth factor or transfusion support Abnormal liver (large organ that helps in many body functions, including digestion, metabolism, and storage of substances) function
Patient description: The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed: Post-void residual: 71 mL Prostate volume (TRUS): 63 mL Prostate-specific antigen (PSA) level: 3.5 ng/mL His recent blood chemistry (3 days ago) was normal: Hgb: 13.6 g/dl WBC: 133000 /mm3 Plt: 370000 /ml PT: 12 second PTT: 34 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hormone-Resistant Prostate Cancer Recurrent Prostate Carcinoma Histologically or cytologically confirmed prostate cancer Must have received prior hormonal therapy, including either medical (luteinizing hormone-releasing hormone [LHRH] agonist) or surgical (orchiectomy) castration Castrate level of testosterone (< 50 ng/dL) Patients treated with LHRH agonists must continue or restart this therapy Must have radiological documentation of either measurable or non-measurable disease Must show documented progression of prostate cancer while on hormonal therapy as indicated by PSA increase Rising PSA is defined as ≤ 2 consecutive rises in PSA taken ≥ 1 week and ≤ 2 months apart PSA >= 5 ng/mL No known brain metastases Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS 60-100%
Patient description: The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed: Post-void residual: 71 mL Prostate volume (TRUS): 63 mL Prostate-specific antigen (PSA) level: 3.5 ng/mL His recent blood chemistry (3 days ago) was normal: Hgb: 13.6 g/dl WBC: 133000 /mm3 Plt: 370000 /ml PT: 12 second PTT: 34 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 2 Patients with type 2 diabetes mellitus receiving antidiabetic treatment (1 or 2 oral agents) during more than 6 months, who need a prolonged action basal insulin to control hyperglycemia Glycosylated hemoglobin > 8,0% and < 10 % Body mass index (BMI) < 40 kg/m2 Voluntary acceptation of the treatment and capability to self inject the insulin glargine Capability and desire to carry out self-determination of glycemia levels using glucometers  Renal function disorder, revealed by a serum creatinine > 177 µmol/l (> 2,0 mg/dl) in Visit 1 or currently undergoing kidney dialysis Acute metabolic acidosis (> 1 episode during the last year) or chronic, including diabetic ketoacidosis Clinical evidence of an active liver disease or serum ALT/AST >2.5 times the upper normality limit A history of unnoticed hypoglycemia Surgical treatment for diabetic retinopathy, (laser photocoagulation or a vitrectomy), during the three months prior to joining the trial, or patient that has needed treatment within three months of entering the trial Pregnancy or breast feeding Not using an adequate birth control method, (only for potentially fertile females) : for example, the use of systemic hormones, (pills or birth control implants), intrauterine devices or a barrier method, (diaphragm with intra-vaginal spermicides, male or female preservative) Known hypersensitivity to insulin glargine or any of its excipients Malignant process, except for basal carcinoma cells during the last five years More than two weeks of continuous treatment with systemic glucocorticoids in the last 6 months
Patient description: The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed: Post-void residual: 71 mL Prostate volume (TRUS): 63 mL Prostate-specific antigen (PSA) level: 3.5 ng/mL His recent blood chemistry (3 days ago) was normal: Hgb: 13.6 g/dl WBC: 133000 /mm3 Plt: 370000 /ml PT: 12 second PTT: 34 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Prostate Cancer Histologically confirmed adenocarcinoma of the prostate Diagnosed within 6 months prior to randomization Patient has been classified as favorable risk as defined by the following Clinical stage T1b, T1c, T2a, or T2b at the time of diagnosis Clinical (diagnostic biopsy) Gleason score ≤ 6 PSA ≤ 10.0 ng/mL Physical examination, rectal examination, and transrectal ultrasound have been done within 6 months prior to randomization and radiographic studies, if indicated, are negative for metastasis Patient is a suitable candidate for radical prostatectomy or radiotherapy ECOG performance status 0, 1, or 2 Patient has a minimum life expectancy of > 10 years
Patient description: The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed: Post-void residual: 71 mL Prostate volume (TRUS): 63 mL Prostate-specific antigen (PSA) level: 3.5 ng/mL His recent blood chemistry (3 days ago) was normal: Hgb: 13.6 g/dl WBC: 133000 /mm3 Plt: 370000 /ml PT: 12 second PTT: 34 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Hepatitis C Healthy, hepatitis C virus (HCV) negative 45 year old healthy adults. Insufficient data are available in adults to judge risk in children In good general health as determined by medical history, physical examination and the following screening labs Complete Blood Count (CBC): Total WBC (White Blood Cell): 3.5-14 thousand/microliter (MCL); Hemoglobin (Hgb): Men: 12.2-18 g/dl and Women: 10.5-17 g/dl Creatinine: Men: less than or equal to 1.4 mg/dl; Women: less than or equal to 1.2 mg/dl Glucose: 50 mg/dl to less than or equal to 109 mg/dl Alanine Aminotransferase (ALT): Men 2-60 units/litre (U/I): Women: 3-40 U/I Aspartate Aminotransferase (AST): Men: 2-50 U/I, Women 2-35 U/I Total bilirubin: Men: less than or equal to 1.5 mg/dl: Women: less than or equal to 1.3 mg/dl Urinalysis: negative or trace protein, negative glucose, less than or equal to 3 Red Blood Cells (RBC)/High Power Field (HPF) and less than or equal to 5WBC/HPF (in nonmenstruating females)  Diabetes Cancer other than squamous cell skin cancer which has been excised History of myocardial infarction or arrhythmia requiring hospitalization Syncope requiring hospitalization Unconsciousness other than a simple concussion Seizures other than febrile seizures as a child <5 years of age Current liver disease (not including Gilbert's disease) Autoimmune disease (does not thyroid disease or vitiligo) Splenectomy Uncontrolled hypertension [blood pressure (BP) >150/90; anti-hypertensive medications are acceptable)
Patient description: The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed: Post-void residual: 71 mL Prostate volume (TRUS): 63 mL Prostate-specific antigen (PSA) level: 3.5 ng/mL His recent blood chemistry (3 days ago) was normal: Hgb: 13.6 g/dl WBC: 133000 /mm3 Plt: 370000 /ml PT: 12 second PTT: 34 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Lower Urinary Tract Symptoms Bladder Outlet Obstruction Diagnosed with Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) BOO indication by a Bladder Outlet Obstruction Index (BOOI) ≥ 20 Patient has a total International Prostate Symptom Score (IPPS) score of ≥ 8 (Inclusion for Baseline also) Patient had a maximum urinary flow rate of ≤ 12 mL/sec, with a voided volume of ≥ 120 mL during free flow in a representative assessment of uroflowmetry  History of urinary retention in preceding 12 months Current urinary tract infection (UTI) or symptomatic and recurrent UTI of > 3 episodes within 12 months Known clinical history or diagnosis of chronic inflammation, stone in bladder or ureter, or other causes of outflow tract obstruction Known diagnosis or history of carcinoma or previous pelvic radiation therapy, except non-metastatic basal or squamous cell carcinoma of the skin that had been treated successfully Clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to Visit 1
Patient description: The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed: Post-void residual: 71 mL Prostate volume (TRUS): 63 mL Prostate-specific antigen (PSA) level: 3.5 ng/mL His recent blood chemistry (3 days ago) was normal: Hgb: 13.6 g/dl WBC: 133000 /mm3 Plt: 370000 /ml PT: 12 second PTT: 34 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hormone-resistant Prostate Cancer Recurrent Prostate Cancer Histologically or cytologically confirmed prostate cancer with a Gleason score available or interpretable and meeting 1 of the following No prior chemotherapy and relatively minimal cancer spread Only one prior taxane-based chemotherapy for aggressive and/or symptomatic disease Must have prostate cancer considered to be hormone refractory or androgen independent by one or more of the following (despite androgen deprivation and anti-androgen withdrawal when applicable) Progression of unidimensionally measurable disease assessed within 28 days prior to initial administration of drug Progression of evaluable but not measurable disease assessed within 28 days prior to initial administration of drug for PSA evaluation and within 42 days for imaging studies (e.g., bone scans) Patients must have nonmeasurable disease (e.g., nuclear medicine bone scans) and non-target lesions (e.g., PSA level) assessed within 28 days prior to initial administration of drug Measurable disease is not required but is allowed Must be surgically or medically castrated If the method of castration was luteinizing hormone-releasing hormone (LHRH) agonists (e.g., leuprolide or goserelin), then the patient must be willing to continue the use of LHRH agonists  Known brain metastases History of allergic reactions attributed to compounds of similar chemical or biological composition to AZD0530 Patients with any of the following conditions that impair the ability to swallow AZD0530 tablets Gastrointestinal tract disease resulting in an inability to take oral medication or requiring IV alimentation Prior surgical procedures affecting absorption Active peptic ulcer disease Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements Patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier Use of specifically prohibited CYP3A4-active agents or substances Prohibited drugs should be discontinued 7 days prior to the administration of the first dose of AZD0530 and for 7 days following discontinuation of AZD0530
Patient description: The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed: Post-void residual: 71 mL Prostate volume (TRUS): 63 mL Prostate-specific antigen (PSA) level: 3.5 ng/mL His recent blood chemistry (3 days ago) was normal: Hgb: 13.6 g/dl WBC: 133000 /mm3 Plt: 370000 /ml PT: 12 second PTT: 34 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Colorectal Cancer Histological or cytological proof of colon or rectal adenocarcinoma Measurable site of disease according to that has not been previously irradiated Must have metastatic colorectal cancer which progressed after first line chemotherapy +/ bevacizumab Blood sample collected within 21 days prior to being registered for protocol therapy for UTG1A1 genotype analysis. (Patients with the UGT1A1 *28 7/7 genotype (homozygosity for the TA7 allele) will be excluded from the Phase I stage of the study. During the Phase II stage of the study, subjects will be allowed to participate but must begin treatment at dose level -1 of irinotecan.) A history of other malignancies (non-colorectal) is allowed, provided it has been curatively treated and demonstrates no evidence for recurrence of that cancer Prior radiation therapy allowed to < 25% of the bone marrow Age ≥ 18 years at the time of consent Written informed consent and HIPAA authorization for release of personal health information Females of childbearing potential and males must be willing to use an effective method of contraception  No more than one prior chemotherapy regimen for metastatic colorectal cancer, at least 28 days prior to being registered for protocol therapy No prior treatment with cetuximab No prior treatment with an mTOR inhibitor No known hypersensitivity to cetuximab, RAD001 (everolimus), other rapamycins (sirolimus, temsirolimus) or to its excipients No treatment with any investigational agent within 28 days prior to being registered for protocol therapy No symptomatic brain metastasis No uncontrolled diabetes as defined by a fasting serum glucose >1.5 x ULN No chronic treatment with systemic steroids or another immuno-suppressive agent No serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to being registered for protocol therapy No liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Patient description: The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed: Post-void residual: 71 mL Prostate volume (TRUS): 63 mL Prostate-specific antigen (PSA) level: 3.5 ng/mL His recent blood chemistry (3 days ago) was normal: Hgb: 13.6 g/dl WBC: 133000 /mm3 Plt: 370000 /ml PT: 12 second PTT: 34 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 41.0-999.0,  Benign Prostatic Hyperplasia Male over the age of 40 Diagnosed with symptomatic/obstructive symptoms secondary to BPH requiring surgical intervention as determined by their urologist Experienced lower urinary tract symptoms (LUTS) secondary to BPH > 3 months in duration IPSS value of > 12 Peak urinary flow < 15mL/sec on voided volume (minimum of 150 ml) Prostate size, as measured by transrectal ultrasonography (TRUS), less than 100cc in volume American Society of Anesthesiology (ASA) classification of physical status, class 1-3 Able to read, understand, and sign the Informed Consent Willing and able to comply with all follow-up requirements including multiple follow-up visits  Transvesically measured post-void residual volume >400 mL Currently in urinary retention Chronic urinary retention Medications impairing bladder contractibility Uncorrectable bleeding disorders or long term anticoagulation that cannot be stopped Recent myocardial infarction or coronary artery stent placement Any of the following diseases which appear to involve the bladder: myasthenia gravis, diabetes neuropathy, multiple sclerosis, spinal cord injury or Parkinson disease Any patient with idiopathic atonic bladder Major pelvic fractures that involved damage to the external urinary sphincter